Varex Imaging CorpVREX

Varex Imaging Corp reported $216.0 million in revenue for the quarter ended 2026-04-03, yet still posted a net loss of $8.1 million as operating income clocked in at $14.4 million. The gap between the top line and the bottom line is wider than the average X-ray beam width, and the cash flow statement shows why: operating cash flow was negative $17.6 million, despite $216 million in sales. Throw in $16.9 million spent on capex and $22.2 million ploughed into R&D, and the math starts to feel like a CT scan: detailed but not always comfortable.

Varex makes components that sit inside medical, dental, veterinary, and security imaging systems sold by OEMs and distributors. Its products range from X-ray tubes and detectors to multi-beam X-ray modules and industrial scanning services, all underpinned by decades of imaging know-how. The company’s web pages tout MBX technology as a way to ditch mechanical motion for electronic beams, promising faster, more robust systems. The pitch is compelling, but the filings show that Varex’s own warranty accrual jumped by $7.6 million in the quarter, a reminder that even the slickest tech can throw out the occasional warranty.

The balance sheet gives a clearer picture than the marketing collateral. Total assets stand at $1.09 billion, with $601.3 million in liabilities and $474.2 million in shareholders’ equity. Cash and equivalents sit at $85.3 million, down from where they started the period. Inventory ballooned by $51.9 million to $346.7 million, which either signals aggressive stocking for future orders or the world’s most expensive just-in-case strategy. Diluted EPS came in at $-0.19 on 42.0 million shares, a figure that might prompt a polite rethink at the shareholder services desk.

If you are hunting for charts, the SEC does not publish them, and Varex’s own pages point to investor relations materials rather than price-time data. The company’s earnings release for Q2 fiscal 2026 is scheduled, so the next set of numbers could shift the story one way or another. Until then, the filings remain the clearest window into a company that sells precision imaging bits but keeps having to explain why the cash register didn’t quite match the sale.

What remains unproven is whether the MBX story, the industrial scanning services pitch, and the OEM customer rollout are translating into margin expansion rather than margin erosion. The warranty line is up; inventory is up; operating cash flow is down. That trio is enough to make any reader reach for a second opinion. For now, the evidence points to a company selling growth stories while the accountants keep the receipts.

The conflict disclosure filing, meanwhile, is a reminder that boards and large shareholders sometimes have interests that don’t neatly align with the small investor. The 13G filings and insider Forms 3 show the usual constellation of institutional holders and executives with disclosed stakes, but the filings don’t reveal any smoking guns-just the background radiation of normal governance filing trail.

If the next quarter delivers positive operating cash flow, a reduction in inventory build, and a net income that isn’t a red ink blot, the story will flip from cautionary to constructive. Until then, treat the polished slides and conference webcasts as marketing, and the 10-Q as the operating manual.